Interview with Tom Keith Roach, President, AstraZeneca South Korea
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
Address: Room A-101, Namsong Bldg., 260-199 Itaewon-dong, Yongsan-gu Seoul, 140-200, Republic of Korea
Tel: +82 2 796 1056
Web: http://crm.cegedim.com/Pages/default.aspx
Cegedim was created in 1969 by Jean-Claude Labrune, a French visionary entrepreneur who focused on the pharmaceutical industry to provide companies with tailored services that help them build successful commercial strategies. In the late 70’s the first Customer Relationship Management solution designed for the Pharmaceutical industry was launched in France and quickly became a standard. With the success of its solutions, Cegedim quickly expanded its business internationally. In May 2007, Cegedim reinforced its global presence and leadership with the acquisition of Dendrite International, a US based company leading the SFA business in the healthcare sector on its continent as well as in Asia. This successful integration gave birth to a uniquely capable global entity providing Life Sciences ready CRM solutions. Today the new company renamed Cegedim Relationship Management does business in over 80 countries and accounts for more than 50 percent of the Cegedim Group’s annual revenues of $1.1 billion. Around the world, Cegedim Relationship Management works with companies behind the scenes to develop the most appropriate solutions that effectively manage the complex regulatory environment, minimize risks and decrease costs. Laurent Labrune, Group founder’s son, is the Chief Executive Officer of the new global organisation since 2007. He brought a wealth of creativity, innovation and expertise with a strong and knowledgeable management team. Altogether, they effectively made strategic choices for the long term leadership of the company.
You have recently taken over the position as head of AstraZeneca in South Korea, after several years working in China. What view did you have of the Korean pharmaceutical sector…
You are one of the foreign multinational directors with most time in the Korean pharmaceutical industry, since 2003. What is your assessment of the direction the market has taken in…
What is KHIDI’s role in supporting the development of the Korean health industry? KHIDI performs three major roles in supporting the Korean health industry, which includes pharmaceuticals, medical devices, cosmetics,…
Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing director. How different are…
Please introduce Handok Pharmaceuticals to our readers, and in particular how it has evolved through partnerships with different multinational companies throughout its history. Handok has developed in a very unique…
Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in…
You have been in South Korea for several months, following some time as Merck’s President in Pakistan. In your opinion, what do you find as the most interesting aspects of…
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
You have recently been appointed as General Manager of Servier in South Korea, after coming from several years working in Europe. What perception did you have of the far-way Korean…
Already an economic powerhouse thriving on export-driven industries such as electronics, automotive and ship-building, South Korea is now looking to boost its potential in the life sciences and to…
Over the last several years we have seen a shift in clinical research from traditional healthcare markets to Asia. How do you see this trend evolving in the coming years?…
See our Cookie Privacy Policy Here
